Clinical Trial Update: A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety of combining emactuzumab with RO7009789 in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Emactuzumab (emactuzumab)
• RO7009789 (RO7009789)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 1 | Status: COMPLETED